It is possible that expression of the inhibitory Siglec-XII served as a dominant-negative receptor that sequestered tumor-suppressive SHP1/2 phosphatases (14, 15), thereby contributing to the oncogenic risk. The gene discussed is NR0B2; the disease is neoplasm.